Effect of Neladenoson Bialanate on Exercise Capacity Among Patients With Heart Failure With Preserved Ejection Fraction: A Randomized Clinical Trial von Shah, Sanjiv J, Voors, Adriaan A, McMurray, John J. V, Kitzman, Dalane W, Viethen, Thomas, Bomfim Wirtz, Antonieta, Huang, Erya, Pap, Akos Ferenc, Solomon, Scott D

Volltext

Finerenone in patients with heart failure with mildly reduced or preserved ejection fraction: Rationale and design of the FINEARTS‐HF trial von Vaduganathan, Muthiah, Claggett, Brian L., Lam, Carolyn S.P., Pitt, Bertram, Senni, Michele, Shah, Sanjiv J., Voors, Adriaan A., Zannad, Faiez, Desai, Akshay S., Jhund, Pardeep S., Viswanathan, Prabhakar, Bomfim Wirtz, Antonieta, Schloemer, Patrick, Lay‐Flurrie, James, McMurray, John J.V., Solomon, Scott D.

Volltext

Rationale and design of the phase 2b clinical trials to study the effects of the partial adenosine A1‐receptor agonist neladenoson bialanate in patients with chronic heart failure... von Voors, Adriaan A., Shah, Sanjiv J., Bax, Jeroen J., Butler, Javed, Gheorghiade, Mihai, Hernandez, Adrian F., Kitzman, Dalane W., McMurray, John J.V., Wirtz, Antonieta Bomfim, Lanius, Vivian, van der Laan, Michael, Solomon, Scott D.

Volltext